{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"284","value":"196"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Overall survival time is defined as the time from treatment start to the date of death due to any cause.","dispersionType":"Full Range","groups":[{"description":"This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).","id":"OG000","title":"Buparlisib (BKM120)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"days"}